Clinical Trials
23 trialsNCT07389876 2026-02-05
G/GEJ
Fudan University
Recruiting
NCT04396821 2025-12-17
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT07139587 2025-09-10
The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Hebei General Hospital
Phase NA Not yet recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04068896 2025-05-29
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Completed
NCT06791148 2025-01-24
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT04294784 2024-11-04
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 2 Terminated
NCT03760822 2024-07-08
SOCRATE
Federation Francophone de Cancerologie Digestive
Phase 2 Active not recruiting
NCT04336098 2024-06-04
Study of SRF617 in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT03283761 2024-02-06
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT06222944 2024-01-25
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Peking University
Phase 2 Not yet recruiting
NCT03304210 2023-11-07
PIPAC-nabpac
University Hospital, Ghent
Phase 1 Completed
NCT02333188 2023-05-31
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
University of Chicago
Phase 1 Completed
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT03801668 2022-01-04
Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
Huazhong University of Science and Technology
Phase 3 Unknown
NCT04443036 2020-06-23
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
China Medical University, China
Phase NA Unknown
NCT04135781 2020-03-23
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage â…¢ Gastric Cancer
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT02574663 2019-10-02
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
Phase 1 Completed
NCT02486601 2019-02-27
FOXAGAST
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Unknown
NCT02229058 2017-07-27
Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer
Sun Yat-sen University
Phase 2 Completed
NCT01980810 2016-06-14
GC-A-003
ChineseAMS
Phase 2 Terminated
NCT00313599 2014-07-02
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT00661167 2012-01-18
Phase II Study of ABI-007 for Gastric Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 2 Completed